Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Active not recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Sarcoma 1Gynecologic 1Dermatologic 1

Conditions

Multiple Myeloma 6Lymphoma, Non-Hodgkin 6Leukemia, Myeloid, Acute 5Lymphoma, Mantle-Cell 4Lymphoma, Large B-Cell, Diffuse 4Precursor Cell Lymphoblastic Leukemia-Lymphoma 3Lymphoma, Follicular 3Lymphoma, B-Cell, Marginal Zone 3Leukemia, Lymphocytic, Chronic, B-Cell 3Hodgkin Disease 3Waldenstrom Macroglobulinemia 2Sezary Syndrome 2Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 2Ovarian Neoplasms 2Mycosis Fungoides 2Lymphoma, T-Cell, Peripheral 2Lymphoma, T-Cell, Cutaneous 2Lymphoma, Large-Cell, Immunoblastic 2Lymphoma, Large-Cell, Anaplastic 2Lymphoma, Extranodal NK-T-Cell 2Lymphoma 2Immunoblastic Lymphadenopathy 2Hematologic Diseases 2Burkitt Lymphoma 2Breast Neoplasms 2Sarcoma, Synovial 1Recurrence 1Neuroblastoma 1Myeloproliferative Disorders 1Myelodysplastic Syndromes 1

Interventions

pazopanib 4tazemetostat 3Doxorubicin 3cixutumumab 2Sorafenib 2Radiotherapy 2Radiation 2Interferon-gamma 2Ifosfamide 2Gemcitabine 2tremelimumab 1temsirolimus 1sapanisertib 1romidepsin 1pembrolizumab 1lorvotuzumab mertansine 1liposomal doxorubicin 1interferon gamma-1b 1indolepropanol phosphate 1durvalumab 1atezolizumab 1Watchful Waiting 1Surgical Procedures, Operative 1Sunitinib 1Rifampin 1Razoxane 1Ramucirumab 1Radiotherapy, Conformal 1Observation 1Leukapheresis 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Has results × Sarcoma, Synovial × Leukapheresis × Clear all
NCT02650986 2025-06-17

Gene-Modified T Cells With or Without Decitabine in Treating Patients With Advanced Malignancies Expressing NY-ESO-1

Roswell Park Cancer Institute

Phase 1/2 Active not recruiting
15 enrolled 12 charts
DermatologicGynecologicSarcoma

Fallopian Tube Neoplasms, Melanoma, Ovarian Neoplasms, Sarcoma, Synovial

Data powered by HemOnc (CC BY 4.0) Colophon âš¡